Memory Loss Clinical Trials

A listing of Memory Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 193 clinical trials
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive

cognitive impairment
postoperative cognitive dysfunction
cognitive deficits
coronary artery bypass graft
  • 26 Jan, 2021
  • 1 location
The Prevention Program for Alzheimer's Related Delirium (PREPARED) Trial

disoriented, have memory loss, and have difficulties maintaining focus. It is an urgent care issue facing elderly patients residing in nursing homes, or long-term care (LTC) facilities. Delirium is a

cognitive assessment
cognitive impairment
  • 23 Jan, 2021
  • 7 locations
CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

> Cholinesterase inhibitor (ChEis) are drugs that are currently used to treat people with memory problems in Parkinson's. The effect of these drugs on falls in Parkinson's has been tested to show that treatment

  • 15 Sep, 2021
  • 19 locations
Optimal Electrical Stimulus During Electroconvulsive Therapy

effect and memory disturbance. Specifically, this study aims to compare the 0.5 ms and 1.0 ms pulse width stimuli. Design: National, register-based randomized trial, unmasked with two treatment

depressive episode
depressed mood
  • 25 Jan, 2021
  • 2 locations
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.

pulmonary arterial hypertension
  • 10 Sep, 2021
  • 13 locations
This Study Tests the Safety of Inhaled BAY1237592 How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure affecting the blood vessels in the lungs due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary hypertension is characterized by the elevation of pressure in …

right heart catheterization
endothelin receptor antagonist
chronic thromboembolic pulmonary hypertension
  • 11 Sep, 2021
  • 58 locations
A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)

The primary purpose of this study is to identify and develop biomarker signatures based on circulating micro ribonucleic acid (RNA) in the blood samples associated with high risk of pulmonary hypertension (PH) to assist in the diagnosis of PH; to estimate the sensitivity, specificity, positive predictive value, and negative predictive …

right heart catheterization
  • 10 Sep, 2021
  • 90 locations
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.

right heart catheterization
endothelin receptor antagonist
heart disease
pulmonary arterial hypertension
  • 10 Sep, 2021
  • 154 locations
A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications for which a positive benefit-risk has been established.

  • 12 Sep, 2021
  • 15 locations
A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH). The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo; the treatment dose with the best efficacy and safety profile will be …

body mass index
right heart catheterization
left ventricular end-diastolic pressure
heart disease
pulmonary arterial hypertension
  • 28 Sep, 2021
  • 29 locations